- Email: [email protected]
New DNA encoding mutant form of HIV virus gp160 without endoproteolysis site and derived attenuated virus useful as AIDS recombinant vaccine
Patent Report sequences for the full-length proviral DNA, structural and genetic components of the virus (extracellular envelope protein, outer core protein, major structural core protein, transmembrane envelope protein and lipid membrane, RNA, reverse-transcriptase, EC 2.7.7.49, and DNA), polyclonal or rnonoclonal antibodies to the structural and genetic components of HIV virus-2-ST, anti-idiotype antibodies, immortalized T-lymphocyte Hut78/B12 or SupTI/LK001 cell cultures infected with the virus, and a cDNA clone, are claimed. The HIV-2-ST virus and its derivatives can be used in diagnosis (by antibody or DNA probe methods), vaccine production and therapy for AIDS and AIDS-related diseases. The virus may be produced in high yield by repeatedly infecting a lymphocyte cell culture with the virus, until a highly infected and immortalized lymphocyte line is developed. 045-90
Peptides from streptococcal M proteins used to prepare vaccines for providing protection against Streptococcus Rockefeller Univ. World 8909 064; 5 October 1989 A polypeptide capable of eliciting an sIgA response in a mammal upon administration is claimed which comprises an amino acid sequence containing at least five amino acid residues, the sequence being the same as a sequence of amino acid residues forming a polypeptide from the conserved exposed region of the M protein of gpA streptococci. Also claimed is an antigen conjugate capable of eliciting an sIgA response in a mammal upon administration comprising the polypeptide covalently linked to a carrier, e.g. cholera toxin B. The polypeptides and conjugates are used in vaccines for eliciting a protective immune response for protection against streptococcal infection (including different serotypes). The vaccines comprise a biologically acceptable diluent and an slgA stimulating amount of a polypeptide. The polypeptides are preferentially obtained by solid-phase synthesis, but may also be obtained by selective enzymatic cleavage of protein-M. 047-90
Hepatitis A,B-combined adjuvanted vaccine containing an inactivated hepatitis A virus antigen and a recombinant hepatitis B virus surface antigen Chemo. Sero. Ther. Res. Inst. Eur 339 667; 2 November 1989 A new hepatitisA,B-combined adjuvanted vaccine comprises an inactivated hepatitis A virus (HAV) antigen, a hepatitis B virus (HBV) surface antigen (HBsAg) and an adjuvant. The inactivated HAV antigen is obtained by cultivating HAVinfected cells susceptible to the virus and inactivating the resulting antigen. The HBsAg is produced using a recombinant transformed by a genetic recombination technique and capable of producing a HBsAg. The resultant polyvalent vaccine protects against both HAV and HBV. It does not induce any interference in the immune response and the immunogenicity of the antigens tends to increase. 048-90 New DNA encoding mutant form of HIV virus gpl60 without endoproteolysis site and derived attenuated virus useful as AIDS recombinant vaccine Leland-Stanford Jr. Univ. Eur 335 635; 4 October 1989 A DNA fragment encoding the entire HIV virus gpl60 protein lacking an endoproteolytic cleavage site (due to site-directed mutagenesis) is new. It contains a prokaryotic origin of replication, a prokaryotic selectable marker and transcriptional initiation and termination regions. Alternatively the origin of replication, regulatory sequences and selectable markers are of eukaryotic origin. The DNA fragment is subjected to mutagenesis to substitute two different amino acids for the natural
292
Vaccine, Vol. 8, June 1990
cleavage site. Also new are: (1) a mutated virus genome whose DNA sequence has two different amino acids substituted for the natural processing signal (a GAATTC to AAAAGA mutation); (2) a method for producing recombinant AIDS vaccine to protect humans, which comprises mammal cells (which are competent for replicating and expressing the HIV virus) transformed with the mutated HIV virus genome; and (3) a recombinant HIV virus vaccine which comprises the expression product of the gpl60 DNA sequence (lacking the endoproteolytic cleavage site). The mutated virus is not infectious. 049-90
New peptide containing T-helper cell epitope of foot-and-mouthdisease virus and optionally B-lymphocyte epitope, useful in vaccine and for potentiating hormone activity Wellcome; Coopers Anita. Health World 8909 228; 5 October 1989 New peptides (I), and their veterinarily acceptable salts have a sequence derived from foot-and-mouth-disease virus (FMDV), are independent, in the F M D V virus structure, of a Blymphocyte epitope, and (in an animal susceptible to infection by F M D V ) can elicit T-lymphocyte help for production of antibody against an antigen. Optionally, amino acids in the sequence can be altered provided T-lymphocyte response is maintained. Also new are similar peptides (Ia) including an amino acid sequence which causes an antibody response to a foreign antigen in such animals. Optionally, other antigens can be coupled to the peptide, e.g. a somatotropin sequence can be coupled to somatostatin or sex hormone. 050-90
Hepatitis A virus antigen comprising inactivated or attenuated complete particles containing RNA and/or immature empty particles, isolated from tissue culture for use as vaccine Nat. Inst. Health Jpn; Denka-Seiken, Chibaken Eur. 339 668; 2 November 1989 A new hepatitis A virus (HAV) comprises inactivated or attenuated HAV particles which may be complete particles containing HAV RNA, or immature empty particles free of HAV RNA. The HAV particles are inactivated with formaldehyde. A new immunogen for obtaining an anti-HAV immunoglobulin for induction of passive immunization comprises inactivated or attenuated HAV particles. The HAV antigen and immunogen may be used as a new vaccine. The HAV complete particles and immature empty particles free of virus RNA have the same antigenicity and immunogenicity, and are capable of inducing neutralizing antibodies against virulent HAV in vivo. 051-90
Recovering protective antigens from crude Bordetella extracts by affinity chromatography on lectin containing adsorbent, useful as vaccine and diagnostic reagent Staatliches Inst. lmmunpraep. Naehrmedien. G D R 268 16l; 24 May 1989 The production of protective antigens (Ag) of the genus Bordetella comprises: (I) coupling lectins able to bind at least two Ag to an adsorbent; (2) contacting the Ag-containing raw material with the resulting column material; (3) elution and separation of Ag; and optionally (4) further processing to produce a pharmaceutical composition. The lectins contain mannose, galactose, glucose and N-acetylglucosamine as carbohydrate component. For production of filamentous haemagglutinin (FHA) and leucocyte-stimulating factor (LSF) from a strain of Bordetella pertussis, the lectins are derived from misteltoe (Viscum album). The adsorbent is an agarose gel, diethylaminoethyl-cellulose, crosslinked dextran, polyacrylamide gel, polymerized maleic anhydride or porous glass. The method described is economical, suitable for large-scale isolation of Ag, and the purity of the final product is greater than the material obtained by sucrose-density centrifugation. The Ag are useful as vaccines and as diagnostic reagents. 052-90
Peptides from streptococcal M proteins used to prepare vaccines for providing protection against Streptococcus Rockefeller Univ. World 8909 064; 5 October 1989 A polypeptide capable of eliciting an sIgA response in a mammal upon administration is claimed which comprises an amino acid sequence containing at least five amino acid residues, the sequence being the same as a sequence of amino acid residues forming a polypeptide from the conserved exposed region of the M protein of gpA streptococci. Also claimed is an antigen conjugate capable of eliciting an sIgA response in a mammal upon administration comprising the polypeptide covalently linked to a carrier, e.g. cholera toxin B. The polypeptides and conjugates are used in vaccines for eliciting a protective immune response for protection against streptococcal infection (including different serotypes). The vaccines comprise a biologically acceptable diluent and an slgA stimulating amount of a polypeptide. The polypeptides are preferentially obtained by solid-phase synthesis, but may also be obtained by selective enzymatic cleavage of protein-M. 047-90
Hepatitis A,B-combined adjuvanted vaccine containing an inactivated hepatitis A virus antigen and a recombinant hepatitis B virus surface antigen Chemo. Sero. Ther. Res. Inst. Eur 339 667; 2 November 1989 A new hepatitisA,B-combined adjuvanted vaccine comprises an inactivated hepatitis A virus (HAV) antigen, a hepatitis B virus (HBV) surface antigen (HBsAg) and an adjuvant. The inactivated HAV antigen is obtained by cultivating HAVinfected cells susceptible to the virus and inactivating the resulting antigen. The HBsAg is produced using a recombinant transformed by a genetic recombination technique and capable of producing a HBsAg. The resultant polyvalent vaccine protects against both HAV and HBV. It does not induce any interference in the immune response and the immunogenicity of the antigens tends to increase. 048-90 New DNA encoding mutant form of HIV virus gpl60 without endoproteolysis site and derived attenuated virus useful as AIDS recombinant vaccine Leland-Stanford Jr. Univ. Eur 335 635; 4 October 1989 A DNA fragment encoding the entire HIV virus gpl60 protein lacking an endoproteolytic cleavage site (due to site-directed mutagenesis) is new. It contains a prokaryotic origin of replication, a prokaryotic selectable marker and transcriptional initiation and termination regions. Alternatively the origin of replication, regulatory sequences and selectable markers are of eukaryotic origin. The DNA fragment is subjected to mutagenesis to substitute two different amino acids for the natural
292
Vaccine, Vol. 8, June 1990
cleavage site. Also new are: (1) a mutated virus genome whose DNA sequence has two different amino acids substituted for the natural processing signal (a GAATTC to AAAAGA mutation); (2) a method for producing recombinant AIDS vaccine to protect humans, which comprises mammal cells (which are competent for replicating and expressing the HIV virus) transformed with the mutated HIV virus genome; and (3) a recombinant HIV virus vaccine which comprises the expression product of the gpl60 DNA sequence (lacking the endoproteolytic cleavage site). The mutated virus is not infectious. 049-90
New peptide containing T-helper cell epitope of foot-and-mouthdisease virus and optionally B-lymphocyte epitope, useful in vaccine and for potentiating hormone activity Wellcome; Coopers Anita. Health World 8909 228; 5 October 1989 New peptides (I), and their veterinarily acceptable salts have a sequence derived from foot-and-mouth-disease virus (FMDV), are independent, in the F M D V virus structure, of a Blymphocyte epitope, and (in an animal susceptible to infection by F M D V ) can elicit T-lymphocyte help for production of antibody against an antigen. Optionally, amino acids in the sequence can be altered provided T-lymphocyte response is maintained. Also new are similar peptides (Ia) including an amino acid sequence which causes an antibody response to a foreign antigen in such animals. Optionally, other antigens can be coupled to the peptide, e.g. a somatotropin sequence can be coupled to somatostatin or sex hormone. 050-90
Hepatitis A virus antigen comprising inactivated or attenuated complete particles containing RNA and/or immature empty particles, isolated from tissue culture for use as vaccine Nat. Inst. Health Jpn; Denka-Seiken, Chibaken Eur. 339 668; 2 November 1989 A new hepatitis A virus (HAV) comprises inactivated or attenuated HAV particles which may be complete particles containing HAV RNA, or immature empty particles free of HAV RNA. The HAV particles are inactivated with formaldehyde. A new immunogen for obtaining an anti-HAV immunoglobulin for induction of passive immunization comprises inactivated or attenuated HAV particles. The HAV antigen and immunogen may be used as a new vaccine. The HAV complete particles and immature empty particles free of virus RNA have the same antigenicity and immunogenicity, and are capable of inducing neutralizing antibodies against virulent HAV in vivo. 051-90
Recovering protective antigens from crude Bordetella extracts by affinity chromatography on lectin containing adsorbent, useful as vaccine and diagnostic reagent Staatliches Inst. lmmunpraep. Naehrmedien. G D R 268 16l; 24 May 1989 The production of protective antigens (Ag) of the genus Bordetella comprises: (I) coupling lectins able to bind at least two Ag to an adsorbent; (2) contacting the Ag-containing raw material with the resulting column material; (3) elution and separation of Ag; and optionally (4) further processing to produce a pharmaceutical composition. The lectins contain mannose, galactose, glucose and N-acetylglucosamine as carbohydrate component. For production of filamentous haemagglutinin (FHA) and leucocyte-stimulating factor (LSF) from a strain of Bordetella pertussis, the lectins are derived from misteltoe (Viscum album). The adsorbent is an agarose gel, diethylaminoethyl-cellulose, crosslinked dextran, polyacrylamide gel, polymerized maleic anhydride or porous glass. The method described is economical, suitable for large-scale isolation of Ag, and the purity of the final product is greater than the material obtained by sucrose-density centrifugation. The Ag are useful as vaccines and as diagnostic reagents. 052-90